Paiania, 22 November 2021 – Lavipharm S.A. announces, in accordance with Regulation 596/2014 / EU and the Regulation of the Athens Stock Exchange, each as in force, that Mr. Vassilis Baloumis assumes the duties of Chief Financial Officer on December 1, 2021 replacing Mr. Spyridon Magliveras, who leaves the company due to retirement. Mr. Baloumis has many years of experience as Chief Financial Officer, with a recent position at Lamda Development SA. He is a graduate in Business Administration of the Athens University of Economics and he holds an Executive MBA from the same University.